A phase I study to determine the maximum tolerated dose of Daunoxome [daunorubicin liposomal] as therapy for the treatment of metastatic breast cancer.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2015
At a glance
- Drugs Daunorubicin liposomal (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 18 Sep 2005 New trial record.